Use of ornidazole in the treatment of anaerobic infection in surgery
Keywords:non-clostridial anaerobic infection, nitro-imidazole, ornidazole
One of the most complex problems of modern surgery is the treatment and prevention of anaerobic infection. Main place in overcoming of this infectious complication is devoted to urgent surgical intervention and correct early empiric antibacterial therapy. Special place in the combined empiric antibacterial treatment is devoted to 5-nitroimidazoles. Modern data about clinical efficacy of ornidazole in the treatment of surgical infectious complications is presented in the article. We performed a comparison of therapeutic activity and physical-chemical properties, pharmacokinetic and pharmacodynamic features of ornidazole with the first representative of 5-nitroimidazole class – metronidazole. Taking into account antiprotozoal and antianaerobic activity of ornidazole, it is recommended to be used in the schemes of combined therapy of severe generalized anaerobic infections and purulent processes of different localization; treatment and prevention of surgical infections after intraabdominal, thoracic, proctological and dental surgical interventions.
Brook I. Spectrum and treatment of anaerobic infections. Jour-nal of Infection and Chemotherapy [Internet]. Elsevier BV; 2016 Jan;22(1):1–13. Available from: https://doi.org/10.1016/j. jiac.2015.10.010
Löfmark S, Edlund C, nord CE. Metronidazole Is Still the Drug of Choice for Treatment of Anaerobic Infections. Clin-ical Infectious Diseases [Internet]. Oxford University Press (OUP); 2010 Jan;50(s1):S16–S23. Available from: https://doi. org/10.1086/647939
Gerych I., VV Vashchuk, TV Khomchenko, OM Morozovuch. Orni-dazole in the surgical treatment of non-clostridial anaerobic infec-tions. Health of Ukraine. 2013; 2–3.
nichitailo ME; Bulik LM. Ornigil use in perioperative prevention and treatment of infectious complications after abdominal surgery. Klinichna hirurgiya, 2012, 4: 65–67.
Volodchenko nP; Shukan SA. non-clostridial anaerobic soft tissue infection. Healthcare of the Far East, 2009, 4:42.
Svetukhin A M. Selected course of lectures on purulent surgery.
A. M. Svetukhin, V.D. Fedorov. M., 2004; 364.
Bereznyakov IG. Antimicrobial resistance; mechanisms of occur-rence and clinical significance: Methodical recommendations. Kharkov, 2006; 72.
Kazachenko AA., Et al. Comparative characteristics of some phar-macological models of chronic heart failure. Experimental and Clinical Pharmacology, 2008, 71.6: 16–19.
Fomin PD. Anaerobic surgical infection. Ukrainian Chemothera-peutic Journal, 2012, 3: 139–147.
Freeman CD, Klutman nE, Lamp KC. Metronidazole. Drugs [Inter-net]. Springer Science and Business Media LLC; 1997 nov;54(5): 679–708. Available from: https://doi.org/10.2165/ 00003495–199754050–00003
Craig WA., Ebert SC. Killing and regrowth of bacteria in vitro. – Scand J Infect Dis 1991; 74(Suppl.): 63–70.
Padeiskaya, En. Preparations of the 5-nitroimidazole group for the treatment of anaerobic and protozoal infections. Infections and Antimicrobial Therapy, 2000, 2.4: 4–7.
Perederi VG; Weaver SM. Modern ideas about the causes and treatment of peptic ulcer disease. The Mystery of Treatment. Ukraine. – 2007;2(38):4–6
Bobrytska LO. Problems and prospects of antimicrobial therapy. The use of ornidazole drugs for the treatment of anaerobic and protozoal infections. Scientific Consultant, 2014, 32.
YU S, WEn A, HE L, SUn L. Therapeutic Effect of Ornidazole on the Anaerobic Infections After Maxillofacial Plastic Surgery. China Pharmacy. 2003(4):20.
Vignaud M, Paugam-Burtz C, Garot M, Jaber S, Slim K, Panis Y, Lu-cet JC, Bourdier J, Morand D, Pereira B, Futier E. Comparison of intravenous versus combined oral and intravenous antimicrobial prophylaxis (COMBInE) for the prevention of surgical site infec-tion in elective colorectal surgery: study protocol for a multicentre, double-blind, randomised controlled clinical trial. BMJ open. 2018 Apr 1;8(4).
Sirvent JM, Rodríguez JI, Rodríguez I, García-Oria M, Roig J, Bonet A. Randomized, prospective and comparative clinical trial of pip-eracillin/tazobactam versus ceftriaxone plus ornidazole in the treatment of biliary tract infections. Medicina clinica. 2003 Dec 6;121(20):761–5.
Rutgeerts P, van Assche G, Vermeire S, D’Haens G, Baert F, no-man M, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo-con-trolled trial. Gastroenterology [Internet]. Elsevier BV; 2005 Apr;128(4):856–61. Available from: https://doi.org/10.1053/j. gastro.2005.01.010
Papi C, Fasci Spurio F, Margagnoni G, Aratari A. Randomized Con-trolled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease. Reviews on Recent Clinical Trials [Internet]. Bentham Science Publishers Ltd.; 2012 nov 1;7(4):307–13. Available from: https://doi.org/10.2174/157488712803989415
Compendium. uElectronic resource – access mode: http://compendium.com.ua/
Gerich ID, et al. Ornidazole in the treatment of surgical non-clos-tridial anaerobic infection. Health of Ukraine (Surgery. Orthope-dics. Traumatology), 2013, 2: 32–33.
Cao Y, Wu X, Chen Y, Guo B, Yu J, Cao G, et al. Improved pharma-cokinetic profile of levornidazole following intravenous infusion of 750mg every 24h compared with 500mg every 12h in healthy Chinese volunteers. International Journal of Antimicrobial Agents [Internet]. Elsevier BV; 2016 Mar;47(3):224–8. Available from: https://doi.org/10.1016/j.ijantimicag.2015.12.007
Shibli JA, Ferrari DS, Siroma RS, Figueiredo LC De, Faveri M DE, Feres M. Microbiological and clinical effects of adjunctive system-ic metronidazole and amoxicillin in the non-surgical treatment of peri-implantitis: 1 year follow-up. Brazilian Oral Research [Inter-net]. FapUnIFESP (SciELO); 2019;33(suppl 1). Available from: https://doi.org/10.1590/1807–3107bor-2019.vol33.0080
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International License